Cuprina Holdings (Cayman) Ltd. (CUPR): Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Cuprina Holdings Limited (CUPR)

Cuprina Holdings (Cayman) Ltd (CUPR) is expanding its presence in Asia by implementing biomedical therapies for chronic wounds. Business revenues are based on the sale of innovative dressings and biological products derived from larvae. Stable working capital and liquidity ratios support operational activities. Analyzing the price-to-sales ratio, it is evident that the 320.90 mark indicates the current market valuation of the asset.

Cuprina Holdings (Cayman) Ltd. (CUPR): Price-to-Revenue Ratio from 05/17/2025 to 11/17/2026

Cuprina Holdings (Cayman) Ltd (CUPR) - metric breakdowns and financial figures

General company analysis:Cuprina Holdings (Cayman) Ltd., CUPR
Signature product of Cuprina Holdings Limited

To assess the investment attractiveness of Cuprina Holdings (Cayman) Ltd (CUPR), it is essential to determine the fairness of the current market price. The price-to-sales ratio reflects how much an investor pays per unit of revenue, making it possible to identify asset overvaluation. For the science-intensive business of the Singaporean management, this indicator serves as a measure of the efficiency of commercializing innovative treatment methods. Low values minimize the risk of overpaying, although a critical minimum may signal capital stagnation.

Competitors of Cuprina Holdings (Cayman) Ltd

HCA (HCA Healthcare) - Market Capitalization-to-Revenue Ratio|Tenet Healthcare Corporation - Market Cap to Revenue|Fresenius Medical (FMS) - Price to Sales|Solventum Corp - P/S Multiple|Price-to-Sales Ratio EHC|Universal Health Services (UHS) - Price-to-Revenue Ratio|DaVita - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue RDNT|OPCH: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue SGRY (Surgery Partners, Inc.)|PINC (Premier, Inc.) - Market Capitalization-to-Revenue Ratio|National Vision - Market Cap to Revenue|Price-to-Revenue Coefficient Progyny Inc (PGNY)|Ardent Health - P/S Multiple|Price-to-Revenue Coefficient Select Medical Corp SEM|ASTH: P/S Multiple|Market Cap to Revenue Ratio MD|USPH (US Physical Therapy Inc) - P/S Multiple|PNTG: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Organogenesis Corp (ORGO)|NUTX (Nutex Health Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple AUNA (Auna S.A.)|SBC Medical Group Holdings Inc (SBC) - Price to Sales|EOLS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio CYH (Community Health Systems Inc)|SKIN (beautyhealth.com) - Market Cap to Revenue|Market Cap to Revenue Ratio MDWD|Price-to-Revenue Ratio biote Corp.|Price to Sales thejoint.com JYNT|P/S Multiple DCGO|Market Cap to Revenue P3 Health PIII|P/S Multiple GANX (Gain Therapeutics Inc.)|P/S Multiple EUDA Health Holdings Limited EUDA|baselmedical.com - P/S Multiple|CLGN: Price-to-Revenue Ratio|CCM: P/S Multiple|AMS: Market Cap to Sales Volume|MRM (MEDIROM Corp) - P/S Multiple|ALBT: Market Capitalization-to-Revenue Ratio|P/S Multiple DHAI|Longevity Health Holdings - Market Cap to Revenue Ratio|Price-to-Revenue Ratio NewGenIvf Group Ltd NIVF|ATIP (atipt.com) - Price-to-Sales Ratio|CMAX: Market Cap to Revenue|Price to Sales Kindly Health|ModivCare (MODV) - Price-to-Revenue Ratio|NVOS (novointegrated.com) - Price-to-Revenue Ratio|SSY (SunLink Health Systems Inc.) - P/S Multiple|BACK (IMAC Holdings Inc) - Market Cap to Sales Volume